Previous close | 261.09 |
Open | 262.15 |
Bid | 265.67 x 100 |
Ask | 266.10 x 100 |
Day's range | 260.41 - 266.38 |
52-week range | 204.44 - 268.21 |
Volume | |
Avg. volume | 530,333 |
Market cap | 11.804B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 12.60 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 01, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 24, 2024--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.